Helping the circulatory system heal itself: Manipulating kinin signaling to promote neovascularization

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 3, 2009, Pages 215-219

  Kränkel, Nicolle ^a   Madeddu, Paolo ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; KALLIKREIN; KININ; NITRIC OXIDE; RANTES; TISSUE KALLIKREIN; VASCULOTROPIN;

ACUTE HEART INFARCTION; ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR GENE THERAPY; CYTOKINE RELEASE; EDITORIAL; ENDOTHELIUM CELL; GENETIC MANIPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ISCHEMIA; LEG ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STABLE ANGINA PECTORIS; VIRAL GENE DELIVERY SYSTEM; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; KALLIKREIN KININ SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; KALLIKREIN-KININ SYSTEM; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION;

EID: 66149172384     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.7.3.215     Document Type: Editorial

References (64)

1. Oeseburg H, Iusuf D, van der Harst P, van Gilst WH, Henning RH, Roks AJ. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension 53, 417-422 (2009).
2. Chao J, Yin H, Gao L et al. Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension 52, 715-720 (2008).
3. Yao YY, Yin H, Shen B et al. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt - glycogen synthase kinase-3β pathway. Cardiovasc. Res. 80, 354-364 (2008).
4. Yin H, Chao L, Chao J. Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci. 82, 156-165 (2008).
5. Brechter AB, Persson E, Lundgren I, Lerner UH. Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-α. Effects dependent on activation of NF-κB and MAP kinases. Bone 43, 72-83 (2008).
6. Medeiros R, Cabrini DA, Ferreira J et al. Bradykinin B1 receptor expression induced by tissue damage in the rat portal vein: a critical role for mitogen-activated protein kinase and nuclear factor-κB signaling pathways. Circ. Res. 94, 1375-1382 (2004).
7. Parenti A, Morbidelli L, Ledda F, Granger, HJ, Ziche M. The bradykinin/ B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J. 15, 1487-1489 (2001).
8. Emanueli C, Minasi A, Zacheo A et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103, 125-132 (2001).
9. Li P, Kondo T, Numaguchi Y et al. Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Hypertension 51, 252-258 (2008).
10. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ. Res. 89, 678-683 (2001).
11. Plendl J, Snyman C, Naidoo S, Sawant S, Mahabeer R, Bhoola KD. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol. Chem. 381, 1103-1115 (2000).
12. Hu DE, Fan TP. [Leu8]des-Arg9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br. J. Pharmacol. 109, 14-17 (1993).
13. Sanchez de Miguel L, Neysari S, Jakob S et al. B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart. Cardiovasc. Res. 80, 106-113 (2008).
14. Miura S, Matsuo Y, Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 41, 1118-1123 (2003).
15. Xia CF, Smith RS Jr, Shen B et al. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47, 752-761 (2006).
16. Segal MS, Shah R, Afzal A et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 55, 102-109 (2006).
17. Obiezu CV, Michael IP, Levesque MA, Diamandis EP. Human kallikrein 4: enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Biol. Chem. 387, 749-759 (2006).
18. Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem. Biophys. Res. Commun. 369, 1169-1173 (2008).
19. Peek M, Moran P, Mendoza N, Wickramasinghe D, Kirchhofer D. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa. J. Biol. Chem. 277, 47804-47809 (2002).
20. Mukai S, Fukushima T, Naka D, Tanaka H, Osada Y, Kataoka H. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. FEBS J. 275, 1003-1017 (2008).
21. Casalino-Matsuda SM, Monzón ME, Forteza RM. Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium. Am. J. Respir. Cell Mol. Biol. 34, 581-591 (2006).
22. Geisert RD, Chamberlain CS, Vonnahme KA, Malayer JR, Spicer LJ. Possible role of kallikrein in proteolysis of insulin-like growth factor binding proteins during the oestrous cycle and early pregnancy in pigs. Reproduction 121, 719-728 (2001).
23. Rosenblum G, Meroueh S, Toth M et al. Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J. Am. Chem. Soc. 129, 13566-13574 (2007).
24. Tschesche H, Michaelis J, Kohnert U, Fedrowitz J, Oberhoff R. Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. Adv. Exp. Med. Biol. 247A, 545-548 (1989).
25. Emanueli C, Salis MB, Van Linthout S et al. Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110, 1638-1644 (2004).
26. Emanueli C, Salis MB, Stacca T et al. Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 38, 136-141 (2001).
27. Nikol S, Baumgartner I, Van Belle E et al.; TALISMAN 201 investigators. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 16, 972-978 (2008).
28. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29, 3477-3496 (2008).
29. Buch PK, Bainbridge JW, Ali RR. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther. 15, 849-857 (2008).
30. Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Maruyama K. Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int. J. Pharm. 354, 49-55 (2008).
31. Smith RS Jr, Gao L, Chao L, Chao J. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol. Chem. 389, 725-730 (2008).
32. Yao YY, Yin H, Shen B, Chao L, Chao J. Tissue kallikrein and kinin infusion. rescues failing myocardium after myocardial infarction. J. Card. Fail. 13, 588-596 (2007).
33. Emanueli C, Caporali A, Krankel N, Cristofaro B, Van Linthout S, Madeddu P. Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia. Front. Biosci. 12, 2003-2012 (2007).
34. Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P. Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in Type 1 diabetic mice. Diabetes 53, 1096-1103 (2004).
35. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47, 25-49 (1995).
36. Fukuhara M, Geary RL, Diz DI et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 35, 353-359 (2000).
37. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94, 2756-2767 (1996).
38. Ohishi M, Ueda M, Rakugi H et al. Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans. J. Hypertens. 15, 1295-1302 (1997).
39. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J. Clin. Invest. 93, 339-346 (1994).
40. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99, 3043-3049 (1999).
41. Messadi-Laribi E, Griol-Charhbili V, Gaies E et al. Cardioprotection and kallikrein - kinin system in acute myocardial ischaemia in mice. Clin. Exp. Pharmacol. Physiol. 35, 489-493 (2008).
42. Marcic B, Deddish PA, Jackman HL, Erdös EG. Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension 33, 835-843 (1999).
43. Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in Type 1 diabetic mice. Arterioscler. Thromb. Vasc. Biol. 25(1), 65-70 (2005).
44. Nagai N, Oike Y, Izumi-Nagai K et al. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest. Ophthalmol. Vis. Sci. 48, 2321-2326 (2007).
45. Kokkonen JO, Kuoppala A, Saarinen J, Lindstedt KA, Kovanen PT. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation 99, 1984-1990 (1999).
46. Dendorfer A, Wolfrum S, Wellhöner P, Korsman K, Dominiak P. Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. Br. J. Pharmacol. 122, 1179-1187 (1997).
47. Osman I, Dai J, Mikhail M et al. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer 107, 2628-2636 (2006).
48. Horiguchi A, Chen DY, Goodman OB Jr et al. Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis. Prostate Cancer Prostatic Dis. 11(1), 79-87 (2008).
49. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
50. Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl Acad. Sci. USA 97, 3422-3427 (2000).
51. Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109, 1801-1809 (2007).
52. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 107, 1164-1169 (2003).
53. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J. Am. Coll. Cardiol. 51, 660-668 (2008).
54. Desrivières S, Lu H, Peyri N, Soria C, Legrand Y, Ménashi S. Activation of the 92 kDa type IV collagenase by tissue kallikrein. J. Cell. Physiol. 157(3), 587-593 (1993).
55. Menashi S, Fridman R, Desrivieres S, Lu H, Legrand Y, Soria C. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann. NY Acad. Sci. 732, 466-468 (1994).
56. Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109(5), 625-637 (2002).
57. Stone OA, Richer C, Emanueli C et al. Critical role of tissue kallikrein in vessel formation and maturation - implications for therapeutic revascularization. Arterioscler. Thromb. Vasc. Biol. DOI: 10.1161/ATVBAHA.108.182139 (2009).
58. Xia CF, Yin H, Yao YY, Borlongan CV, Chao L, Chao J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene Ther. 17(2), 206-219 (2006).
59. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 285(4), H1479-H1488 (2003).
60. Kränkel N, Katare RG, Siragusa M et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ. Res. 103(11), 1335-1343 (2008).
61. Hagiwara M, Shen B, Chao L, Chao J. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum. Gene Ther. 19, 807-819 (2008).
62. Spinetti G, Kraenkel N, Fortunate O, Madeddu PR. Human tissue kallikrein overexpression confers upon human endothelial progenitor cells enhanced invasive and pro-angiogenic activity. Circulation 118, S_479 (2008).
63. Hollemann D, Budka H, Löscher WN, Yanagida G, Fischer MB, Wanschitz JV. Endothelial and myogenic differentiation, of hematopoietic progenitor cells in inflammatory myopathies. J. Neuropathol. Exp. Neurol. 67, 711-719 (2008).
64. Seita J, Asakawa M, Ooehara J et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 111, 1903-1912 (2008).